Lexaria Bioscience Corp. (LEXX) - Dilution Analysis

10-Q filing | 21.4M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholders of up to 2,754,756 shares of our common stock issuable upon the exercise of warrants.

8-K filing: Lexaria Bioscience Corp. completed a registered direct offering and concurrent private placement, selling 2,661,600 shares of common stock at $1.315 per share and issuing warrants to purchase up to 2,661,600 shares at an exercise price of $1.19 per share, raising gross proceeds of approximately $3.5 million. ($3.5M proceeds)

S-1/A filing: This prospectus relates to the resale by the selling stockholders of up to 2,760,000 shares of Lexaria Bioscience Corp.'s common stock, issuable upon the exercise of outstanding warrants.

10-Q filing | 15.8M shares outstanding

8-K filing: Lexaria Bioscience Corp. closed a registered direct offering, issuing 1,925,000 shares of common stock and pre-funded warrants to purchase 75,000 shares, raising gross proceeds of $2 million. ($2.0M proceeds)

10-Q filing | 15.8M shares outstanding

S-3 filing: Lexaria Bioscience Corp. files an S-3 form to offer and sell up to $50,000,000 in aggregate of common stock.

10-Q filing | 16.7M shares outstanding

POS AM filing: This prospectus relates to the resale of up to 314,287 shares of common stock issuable upon the exercise of outstanding warrants.

10-K filing | 8.1M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time by the selling stockholder identified herein of up to 4,551,019 shares of common stock underlying certain private placement warrants.

8-K filing: Lexaria Bioscience Corp. closed a registered direct offering and a concurrent private placement on October 16, 2024, raising gross proceeds of approximately $5.0 million through the issuance of 1,633,987 shares of common stock and warrants exercisable for up to 4,551,019 shares. ($5.0M proceeds)

10-Q filing | 15.8M shares outstanding

S-1 filing: Lexaria Bioscience Corp. is offering 2,917,032 shares of common stock issuable upon the exercise of an outstanding warrant.

8-K filing: Lexaria Bioscience Corp. entered into a warrant exercise agreement with an existing accredited investor to exercise an outstanding Common Stock Purchase Warrant to purchase up to an aggregate of 2,917,032 shares of the Company's common stock, and in consideration, the Investor received a new unregistered Common Stock Purchase Warrant to purchase up to an aggregate of 2,917,032 shares of the Company's common stock in a private placement. ($5.06M proceeds)

10-Q filing | 12.4M shares outstanding

S-1 filing: This prospectus relates to the resale by selling stockholders of up to 1,612,989 shares of common stock issuable upon the exercise of outstanding warrants issued on February 16, 2024.

8-K filing: Lexaria Bioscience Corp. closed a registered direct offering and a concurrent private placement on February 16, 2024, raising gross proceeds of approximately $3.6 million through the sale of common stock and warrants. ($3.6M proceeds)

POS AM filing: This prospectus relates to an aggregate of 1,261,804 shares of our common stock, par value $0.001 per share, upon the exercise of warrants to purchase 1,261,804 shares of common stock that were issued as part of our May 11, 2023 public offering (the "Warrants").

10-Q filing | 10.3M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 1,618,330 shares of common stock issuable upon the exercise of outstanding warrants by the selling stockholder.

10-K filing | 6.0M shares outstanding

8-K filing: Lexaria Bioscience Corp. received a letter from Nasdaq confirming compliance with the minimum bid price requirement. The company also received notices of warrant exercise for 468,279 common shares at $0.95 per share and a request for the exercise of 303,058 pre-funded warrants at $0.0001 per share. ($0.44M proceeds)

8-K filing: Lexaria Bioscience Corp. closed a registered direct offering and a private placement offering on October 3, 2023, raising gross proceeds of $1,569,780.10 through the issuance of shares, pre-funded warrants, and private placement warrants.

10-Q filing | 8.1M shares outstanding

8-K filing: Lexaria Bioscience Corp. entered into a placement agency agreement with Maxim Group LLC for an offering of 2,106,000 units, each consisting of one share of common stock and one warrant, at a public offering price of $0.95 per unit, and also entered into a security purchase agreement with certain institutional investors for up to an aggregate of $247,000 of Units. ($2.0M proceeds)

S-1/A filing: This S-1/A filing relates to the offering of Common Units and Pre-Funded Units, each including shares of common stock and warrants, with Maxim Group LLC acting as the placement agent.

10-Q filing | 6.0M shares outstanding

10-Q filing | 6.0M shares outstanding

POS AM filing: This prospectus relates to the offering and resale by the selling stockholders of up to 330,860 shares of common stock, including shares issuable upon the exercise of outstanding warrants.

POS AM filing: This prospectus relates to an aggregate of 1,659,448 shares of our common stock, par value $0.001 per share, upon the exercise of outstanding warrants.

10-K filing | 5.7M shares outstanding

8-K filing: Lexaria issued 103,500 options to employees, directors and officers on August 29, 2022 and 3,400 options to a director on September 2, 2022.

10-Q filing | 6.0M shares outstanding

10-Q filing | 6.0M shares outstanding

S-3 filing: Lexaria Bioscience Corp. may offer and sell up to $50,000,000 in aggregate of common stock.

10-Q filing | 5.7M shares outstanding

POS AM filing: This prospectus relates to the offering and resale by the selling stockholders of up to 434,085 shares of common stock, including 352,763 shares issuable upon the exercise of outstanding warrants.

POS AM filing: This prospectus relates to the issuance of up to 1,659,448 shares of our common stock upon the exercise of warrants.

8-K filing: Lexaria Bioscience Corp. issued 224,299 common shares to SRAX, Inc. at a deemed price of $5.35 per share for aggregate consideration of $1,200,000, as consideration for media services. ($1.2M proceeds)

10-K filing | 5.7M shares outstanding

8-K filing: Lexaria Bioscience Corp. announced the issuance of 580,189 common shares pursuant to warrant exercises at US$6.58 per share, resulting in gross proceeds of $3,817,643. ($3.82M proceeds)

10-Q filing | 5.1M shares outstanding

8-K filing: Lexaria Bioscience Corp. issued share purchase warrants exercisable into an aggregate of 300,000 common voting shares to three of its consultants.

10-Q filing | 5.1M shares outstanding

POS AM filing: This POS AM filing relates to the offering and resale of up to 483,568 shares of common stock by selling stockholders, including shares issuable upon exercise of warrants, and the potential issuance of shares upon cash exercise of warrants for approximately $5,292,003.

POS AM filing: This prospectus relates to the offering and resale by selling stockholders of up to 483,568 shares of common stock, including shares issuable upon exercise of outstanding warrants, and the potential issuance of shares upon cash exercise of these warrants.

10-Q filing | 5.1M shares outstanding

8-K filing: Lexaria Bioscience Corp. completed a public offering of 2,102,856 shares of common stock at $5.25 per share along with warrants, and also enacted a 1-for-30 reverse stock split. ($11.04M proceeds)

S-1/A filing: This is an S-1/A filing outlining the terms and expenses related to a proposed offering, including filing fees, legal expenses, and underwriter costs. It also covers the application of net proceeds, delivery of earnings statements, stabilization, and internal controls.

S-1/A filing: The company is offering for sale 1,066,666 shares of common stock along with warrants and is offering pre-funded warrants to purchase up to 1,066,666 shares of common stock, also with warrants.

S-1 filing: This is an S-1 filing for an offering of common stock and warrants, as well as pre-funded warrants and warrants. The offering also includes an underwriter option to purchase additional shares and/or warrants.

10-K filing | 90.0M shares outstanding

8-K filing: Lexaria Bioscience Corp. issued 347,222 common shares to IRTH Communications, LLC as compensation for investor relations services, with a deemed value of $100,000 or $0.288 per share. ($0.1M proceeds)

10-Q filing | 89.6M shares outstanding

S-1 filing: This S-1 filing details the offering and resale of up to 22,514,337 shares of common stock by selling stockholders, including shares issuable upon the exercise of outstanding warrants.

8-K filing: Lexaria Bioscience Corp. sold 8,028,254 shares of common stock and warrants to purchase 8,028,254 shares for gross proceeds of approximately $2,064,998 in the first tranche of a private placement. ($2.06M proceeds)

10-Q filing | 80.7M shares outstanding

10-Q filing | 80.7M shares outstanding